Bavarian Nordic A/S (BVNRY)
| Market Cap | 2.79B |
| Revenue (ttm) | 873.91M |
| Net Income (ttm) | 101.64M |
| Shares Out | n/a |
| EPS (ttm) | 1.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,934 |
| Open | 11.74 |
| Previous Close | 11.92 |
| Day's Range | 11.69 - 12.12 |
| 52-Week Range | 11.19 - 14.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 15, 2024 |
About Bavarian Nordic
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phas... [Read more]
News
Bavarian Nordic signs agreement with UNICEF for one million mpox vaccines
Bavarian Nordic said on Thursday it has signed an agreement with the UNICEF for one million mpox vaccines, which include 500,000 doses that were committed by the Gavi vaccine alliance.
Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines
COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced an agreement with UNICEF for the supply of 1 million doses of the MVA-BN® mpox vaccine for countries in Africa...
Bavarian Nordic Upgrades its Financial Guidance for 2024
COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) upgrades its financial guidance for 2024.
Bavarian Nordic said to have won $63M mpox vaccine contract from U.S.
Bavarian Nordic (BVNRY) secures $63M U.S. government contract to manufacture components for Jynneos, its FDA approved vaccine for smallpox and mpox. Read more here.
Bavarian Nordic gets $63 million US government order for small pox, mpox vaccine
Bavarian Nordic has received an order worth $63 million from the U.S. government to produce additional bulk product and the final freeze-dried doses of its mpox and smallpox vaccine, Jynneos, it said ...
Bavarian Nordic Awarded USD 63 Million from the U.S. Government for Production and Supply of Additional Smallpox/Mpox Vaccines
COPENHAGEN, Denmark, September 24, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that it has received an additional order valued at USD 63 million from the Biomedical Advanced Research and De...
Bavarian Nordic Receives EMA Approval of Mpox Vaccine for Adolescents
COPENHAGEN, Denmark, September 19, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the European Commission has adopted the Committee for Medicinal Products for Human Use (CHMP) recommendat...
Bavarian Nordic in pact with global vaccine group, Gavi for 500K mpox vaccines
Bavarian Nordic's (BVNRY) agrees to supply 500,000 doses of its MVA-BN mpox vaccine to Africa as part of a deal with Gavi, the global vaccine alliance. Read more here.
Gavi to buy 500,000 mpox vaccine doses from Bavarian Nordic
The global vaccine group Gavi will buy 500,000 doses of Bavarian Nordic's mpox vaccine, its first purchase of the shot to help battle an outbreak in parts of Africa, the group said on Wednesday.
Gavi Signs Agreement with Bavarian Nordic to Rapidly Secure 500,000 Doses of Mpox Vaccines for Africa
COPENHAGEN, Denmark and GENEVA, Switzerland, September 18, 2024 – Bavarian Nordic A/S (OMX: BAVA) and Gavi, the Vaccine Alliance today announced an advance purchase agreement (APA) to secure 500,000 d...
UK Secures Additional Doses Of Bavarian Nordic Mpox Vaccine To Combat New Variant Threat
The U.K. government has secured over 150,000 doses of the mpox vaccine from Bavarian Nordic A/S (OTC: BVNRY) (OTC: BVNKF) to strengthen the nation's defenses against clade I mpox . The vaccines will...
UK government buys over 150,000 doses of Bavarian Nordic's mpox vaccine
The UK government has ordered more than 150,000 doses of Bavarian Nordic's mpox vaccine to boost its preparedness against a new form of the virus currently spreading in African countries.
First mpox vaccine approved by WHO in effort to combat disease in Africa
The World Health Organisation has granted its first authorisation for an mpox vaccine in adults, produced by Bavarian Nordic A/S. This marks a significant step in combating the disease, especially in ...
Monkeypox: WHO prequalifies first vaccine; know all about it
The WHO has added the MVA-BN vaccine by Bavarian Nordic A/S to its list of prequalified vaccines against monkeypox, aiming to enhance access in high-need regions. The vaccine is effective at 76% with ...
Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine
COPENHAGEN, Denmark, September 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that the Company has obtained prequalification from the World Health Organization (WHO) for IMVANEX® (MVA-BN®)...
WHO clears Bavarian Nordic's vaccine as first shot against mpox
The World Health Organization said on Friday it had cleared Bavarian Nordic's vaccine as the first shot against mpox.
Bavarian Nordic sees potential to ramp up mpox vaccine capacity
Bavarian Nordic said on Thursday it could supply 13 million doses of its mpox vaccine by the end of 2025, up from a previous forecast of 10 million doses, and is exploring options to significantly exp...
Bavarian Nordic Provides Update on the Mpox Vaccine Supply Situation
COPENHAGEN, Denmark, September 12, 2024 – Bavarian Nordic A/S (OMX: BAVA), the vaccine manufacturer of MVA-BN®, the only approved non-replicating smallpox and mpox vaccine (marketed as JYNNEOS®, IMVAM...
One Bavarian Nordic Shot 58% Effective Against Mpox, Study Shows
Bavarian Nordic A/S’s smallpox vaccine was moderately effective in preventing mpox infection after a single dose, according to a study in Ontario, Canada, where the shot probably helped curb a 2022 ou...
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
COPENHAGEN, Denmark, September 6, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company's shares/related securities by persons holding m...
Mpox Vaccines: Challenges Persist as Congo Receives First Batch Of Doses Almost 2 Years After It Declared Epidemic
On Thursday, the European Commission said around 100,000 mpox vaccine doses arrived in the Democratic Republic of Congo (DRC), making these the first delivery of the vaccine to the country . A second ...
EU-donated mpox vaccines arrive in DRC after WHO declared health emergency
The 100,000 doses of the MVA-BN vaccine, manufactured by the Danish company Bavarian Nordic, have been donated through HERA, the EU's agency for health emergencies.
Bavarian Nordic stock slides on Moderna mpox vaccine study
Bavarian Nordic’s (BVNKF) Europe-listed shares fell 7% Thursday, the day after a study showed Moderna's (MRNA) mpox vaccine appeared to be more effective than Bavarian's Jynneos.
First Doses of Bavarian Nordic's Mpox Vaccine Now Arriving in the Democratic Republic of Congo
COPENHAGEN, Denmark, September 5, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the first doses of its mpox vaccine, MVA-BN®, also known as JYNNEOS®, has arrived today in the Democratic ...
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
COPENHAGEN, Denmark, September 5, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 7,164,460 as a consequence of employees' e...